

Pascal Juillerat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2848671/publications.pdf>

Version: 2024-02-01

51
papers

5,043
citations

279798

23
h-index

189892

50
g-index

53
all docs

53
docs citations

53
times ranked

5838
citing authors

#	ARTICLE	IF	CITATIONS
1	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 128-140.	8.1	45
2	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	8.1	49
3	Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210741.	3.2	5
4	Vacuum-Sponge Therapy Placed through a Percutaneous Gastrostomy to Treat Spontaneous Duodenal Perforation. <i>Case Reports in Gastroenterology</i> , 2022, 16, 223-228.	0.6	1
5	Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100104.	3.6	15
6	Varicella Zoster Virus in Inflammatory Bowel Disease Patients: What Every Gastroenterologist Should Know. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 316-325.	1.3	5
7	Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. <i>Advances in Therapy</i> , 2021, 38, 660-677.	2.9	13
8	Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. <i>United European Gastroenterology Journal</i> , 2021, 9, 398-406.	3.8	7
9	Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00298.	2.5	3
10	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. <i>British Journal of Pharmacology</i> , 2021, 178, 3157-3175.	5.4	9
11	Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 912-919.e2.	1.0	12
12	Risk of Vaccine-Preventable Infections in Swiss Adults with Inflammatory Bowel Disease. <i>Digestion</i> , 2021, 102, 956-964.	2.3	4
13	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. <i>Microorganisms</i> , 2021, 9, 1752.	3.6	6
14	Fatigue in inflammatory bowel disease and its impact on daily activities. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 138-149.	3.7	25
15	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. <i>BMC Gastroenterology</i> , 2021, 21, 310.	2.0	5
16	A Response to: Letter to the Editor Regarding “Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland”. <i>Advances in Therapy</i> , 2021, , 1.	2.9	0
17	Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. <i>Digestion</i> , 2020, 101, 683-691.	2.3	12
18	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	1.3	741

#	ARTICLE	IF	CITATIONS
19	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2019-2029.e11.	4.4	64
20	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	1.3	478
21	Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S807-S814.	1.3	7
22	TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. <i>Digestion</i> , 2020, 101, 16-26.	2.3	46
23	Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. <i>Digestion</i> , 2020, 101, 69-82.	2.3	49
24	Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations. <i>Digestion</i> , 2020, 101, 83-97.	2.3	19
25	Management of the Elderly Inflammatory Bowel Disease Patient. <i>Digestion</i> , 2020, 101, 105-119.	2.3	27
26	Microbial network disturbances in relapsing refractory Crohn's disease. <i>Nature Medicine</i> , 2019, 25, 323-336.	30.7	277
27	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). <i>International Journal of Epidemiology</i> , 2019, 48, 385-386f.	1.9	26
28	Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 767-781.	3.8	67
29	High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 1130-1141.	0.4	21
30	Swiss Delphi study on iron deficiency. <i>Swiss Medical Weekly</i> , 2019, 149, w20097.	1.6	4
31	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 612-620.	1.6	30
32	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. <i>PLoS ONE</i> , 2018, 13, e0199664.	2.5	35
33	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	1.3	1,547
34	Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS). <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 163-170.	1.9	10
35	The ESRP1-GPR137 axis contributes to intestinal pathogenesis. <i>ELife</i> , 2017, 6, .	6.0	24
36	Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 829-835.e1.	4.4	260

#	ARTICLE	IF	CITATIONS
37	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	1.3	577
38	High Rates of Smoking Especially in Female Crohn's Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation—Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 819-829.	1.3	52
39	Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 60-70.	1.9	34
40	The accuracy of self-reported medical history: A preliminary analysis of the promise of internet-based research in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 349-356.	1.3	34
41	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1427-1437.	1.3	31
42	Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated at 6 Boston Academic Hospitals. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2457-2463.	1.9	22
43	Infliximab for Crohn's disease in the Swiss IBD Cohort Study. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1352-1357.	1.6	9
44	Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1449-1456.	1.5	6
45	Cohort Profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). <i>International Journal of Epidemiology</i> , 2009, 38, 922-931.	1.9	140
46	Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel — EFACT II. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 241-249.	1.3	5
47	Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 131-141.	1.3	39
48	Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis. <i>Dermatology</i> , 2007, 215, 245-251.	2.1	64
49	Extraintestinal Manifestations of Crohn's Disease. <i>Digestion</i> , 2007, 76, 141-148.	2.3	39
50	EFACT II: Project and Methods. <i>Digestion</i> , 2007, 76, 84-91.	2.3	6
51	Drug Safety in Crohn's Disease Therapy. <i>Digestion</i> , 2007, 76, 161-168.	2.3	18